Reblozyl
What Reblozyl is used for
Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Reblozyl
- Active substance
- luspatercept
- Disease area
- Anemia; Myelodysplastic Syndromes; beta-Thalassemia
- Medicine group
- Other antianemic preparations
- ATC code
- B03XA06
- Marketing authorisation holder
- Bristol Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2020
Official information
In the USA
Same active substance: Reblozyl
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Reblozyl used for?
Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta th…
What is the active substance in Reblozyl?
Reblozyl contains luspatercept.
Who makes Reblozyl?
The EU marketing authorisation holder is Bristol Myers Squibb Pharma EEIG.
Is Reblozyl an orphan medicine?
Yes. Reblozyl is designated an orphan medicine in the EU, for a rare disease (Anemia; Myelodysplastic Syndromes; beta-Thalassemia).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU